Skip to content

Use of Dexamethasone in Uterine Artery Embolization

The Effect of Dexamethasone on Inflammatory Response After Uterine Artery Embolization

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02056717
Enrollment
64
Registered
2014-02-06
Start date
2014-04-30
Completion date
2015-04-30
Last updated
2015-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenomyosis, Uterine Myoma

Brief summary

The primary purpose of this study is to investigate the effects of dexamethasone on inflammatory reactions after uterine artery embolization. The secondary purpose of this study it to investigate the effects of dexamethasone on postembolization syndrome (severe pain, nasea and vomiting).

Interventions

DRUGDexamethasone

Administration of dexamethasone 10 mg IV 1 h before UAE

DRUGNormal saline

Administration of normal saline 2 mL IV 1 h before UAE

Sponsors

Severance Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Uterine artery embolization due to multiple myoma or adenomyosis

Exclusion criteria

* Diabetic mellitus * Steroid administration * Liver or kidney dysfuntion * High baseline CRP or leukocytosis (\>11,000/μL ) * Drug allergy

Design outcomes

Primary

MeasureTime frameDescription
Inflammatory reactions24 hoursCRP, WBC, neutrophil (%), cortisol : pre-UAE, post-UAE 12 h, post-UAE-24 h IL-6 : pre-UAE, post-UAE-24 h

Secondary

MeasureTime frameDescription
Nausea and vomiting24 hoursImmediately after UAE, post-UAE 1, 2, 4, 6, 8, 12, 24 h
Sucessful rate at 3 month after UAE3 monthUtrerine volume and complete necrosis incidence
Pain24 hoursImmediately after UAE, post-UAE 1, 2, 4, 6, 8, 12, 24 h

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026